Is Buying Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Here Good Idea?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Logo

The stock of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) registered a decrease of 8.58% in short interest. OPNT’s total short interest was 142,700 shares in January as published by FINRA. Its down 8.58% from 156,100 shares, reported previously. With 24,700 shares average volume, it will take short sellers 6 days to cover their OPNT’s short positions.

The stock increased 5.17% or $0.7 during the last trading session, reaching $14.24. About 28,955 shares traded or 8.32% up from the average. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) has declined 47.22% since January 10, 2018 and is downtrending. It has underperformed by 47.22% the S&P500.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company has market cap of $54.60 million. The firm offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It currently has negative earnings. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.